Pacific Biosciences of California, Inc. (PACB) Posts Q2 EPS Loss of $0.42
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts PACB Hot Sheet
Join SI Premium – FREE
Pacific Biosciences of California, Inc. (NASDAQ: PACB) reported Q2 EPS of ($0.42), $0.20 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $10.6 million versus the consensus estimate of $4.1 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- enVVeno Medical (NVNO) Misses Q3 EPS by 302c
- Regal-Beloit (RBC) Tops Q3 EPS by 21c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
